

**From:** [Dodge, Gail](#)  
**To:** [Dodge, Gail](#)  
**Cc:** [Whitfield, Tiffany L.](#)  
**Subject:** Draft Monday Matters: Research Restart  
**Date:** Monday, March 15, 2021 8:01:48 AM

---

Dear Colleagues:

Please see the email below from Adam Rubenstein about the research restart process. Non-human subjects research will go back to stage 3. An important part of that is highlighted in red. Undergraduates can be supervised in on-campus research this summer as long as the other safety requirements are fulfilled. New requests for stage 3 research restart will go through your chair and be handled by Rodger Harvey as before.

Please let me know if there is anything we can do to assist you with getting research programs fully restored.

Best Regards,  
Gail

---

**From:** Adam Rubenstein <ARubenst@odu.edu>  
**Date:** Friday, March 12, 2021 at 3:37 PM  
**Subject:** Modification to Research Restart - Partial Stage 3

Good Afternoon, Deans and Center Directors,

After the large spike in COVID-19 cases within the state, numbers have been decreasing in our region. As such we are implementing a partial return to Stage 3 of our Research Restart Plan.

**Non-human subjects:** Effective immediately, non-human subjects research in the laboratory and field is back to Stage 3. As before, maximum room occupancy will be calculated at 1 person per 200 sq ft and studies of longer duration are allowed. **Inclusion of undergraduates as members of the research team does not require extra justification.** Studies that have been functioning at Stage 1 or 2 as well as studies previously approved at Stage 3 do NOT need to reapply. Only new projects require submission of a research restart form.

**Human subjects:** Human subjects research will remain at Stage 2 levels for the time being. This only allows in-person data collection in clinical settings that is standard-of-care or takes advantage of patient presence without additional risk. All other work should continue using remote/virtual methodologies. A decision regarding in-person data collection in laboratory settings will be revisited as the vaccination roll-out expands in Virginia.

As always, please feel free to direct questions to myself, Karen Eck, or Morris Foster. Thank you for your help in ensuring this campus safety as we continue the Spring semester.

Best,

Adam

**Adam J. Rubenstein, Ph.D.**

Assistant Vice President for Research Compliance • Office of Research  
Old Dominion University  
4111 Monarch Way, Suite 203 • Norfolk, VA 23508

Office: 757.683.3686 • Fax: 757.683.5902  
<https://www.odu.edu/impact/compliance>